Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Archie Meeties who wrote (14220)	11/19/2004 9:47:51 AM
From: Biomaven	Respond to of 52153

In Non-Small Cell Lung Cancer does stage II III recurrent disease carry a worse prognosis than IIIb/IV first onset? I don't personally know the answer to this, but I do have a couple of comments: 1. IIIb/IV first onset with PS2 has such a miserable prognosis that it's hard to imagine that any group is going to be significantly worse. 2. The key issue is not really their prognosis untreated, but their prognosis when given taxol+carboplatin. So while I'm in general agreement about your staging comment (you can see the same phenomenon now in breast cancer, calling into question the benefits of early screening), to the extent you de-link from the previous trials you are more-or-less in uncharted waters. Part of the problem is that there have been very few trials at all of PS2 NSCLC patients - they generally do so badly that investigators have mostly run away from them. Peter